Stockscreener 앱 받기
8.43
1.93%
0.16
시간 외 거래:
7.91
-0.52
-6.17%
전일 마감가:
$8.27
열려 있는:
$8.47
하루 거래량:
5,713
Relative Volume:
0.10
시가총액:
$8.01M
수익:
-
순이익/손실:
$-40.36M
주가수익비율:
-0.1733
EPS:
-48.648
순현금흐름:
$-21.40M
1주 성능:
-4.53%
1개월 성능:
+57.57%
6개월 성능:
-5.70%
1년 성능:
-16.12%
1일 변동 폭
$8.1232
$8.9943
1주일 범위
$7.9405
$9.395
52주 변동 폭
$3.82
$20.99
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.43 | 7.86M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
TransCode Therapeutics Updates Preferred Stock Ownership Limits - TipRanks
Form 13D/A TransCode Therapeutics For: 17 July By Investing.com - Investing.com Canada
TransCode Therapeutics (RNAZ) investor to convert preferred stock toward 9.99% stake - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) raises Series C ownership cap to 9.99% - Stock Titan
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine
Understanding Momentum Shifts in (RNAZ) - Stock Traders Daily
Price to earnings forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to book forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to sales forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
RNAZ | TransCode Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (RNAZ) Movement - Stock Traders Daily
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps - TipRanks
Nasdaq review delays TransCode (NASDAQ: RNAZ) vote on preferred conversion - Stock Titan
TransCode Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAZ) - TradingView
TransCode Therapeutics, Inc. Actuals & Estimates (BOATS:RNAZ) - TradingView
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RNAZ Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Discipline and Rules-Based Execution in RNAZ Response - Stock Traders Daily
TransCode Highlights Progress of Lead RNA Cancer Therapeutic - TipRanks
Transcript : TransCode Therapeutics, Inc.Special Call - marketscreener.com
TransCode Therapeutics posts investor presentation detailing Phase 1a safety, Phase 2a plan and $12.8M cash - TradingView
TransCode Therapeutics (NASDAQ: RNAZ) furnishes new investor presentation via Form 8-K - Stock Titan
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TransCode Therapeutics (RNAZ) Rallies 3.27% as Biotech Stock Tests Key ResistanceFactor Crowding - newsline.com
RNAZ Technical Analysis & Stock Price Forecast - Intellectia AI
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan
RNAZ: Introducing RNA Therapeutics - Yahoo Finance
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com
RNAZ Q4 2024 Earnings: Wider-than-expected loss amid pre-revenue stageNet Profit Margin - newsline.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Sahm
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks
TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia
TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire
TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria
TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks
TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines By Investing.com - Investing.com South Africa
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
2.11%
자본화:
|
볼륨(24시간):